An injectable liposome-anchored teriparatide incorporated gallic acid-grafted gelatin hydrogel for osteoarthritis treatment.

Li G, Liu S, Chen Y, Zhao J, Xu H, Weng J, Yu F, Xiong A, Udduttula A, Wang D, Liu P, Chen Y, Zeng H

Nature communications31 May 2023Cited by 178 (Europe PMC)

PMID37258510PMCIDPMC10232438DOI10.1038/s41467-023-38597-0PepBankPUB-37258510

Summary

Intra-articular injection of therapeutics is an effective strategy for treating osteoarthritis (OA), but it is hindered by rapid drug diffusion, thereby necessitating high-frequency injections. Hence, the development of a biofunctional hydrogel for improved delivery is required. In this study, we introduce a liposome-anchored teriparatide (PTH (1-34)) incorporated into a gallic acid-grafted gelatin injectable hydrogel (GLP hydrogel). We show that the GLP hydrogel can form in situ and without affecting knee motion after intra-articular injection in mice. We demonstrate controlled, sustained release of PTH (1-34) from the GLP hydrogel. We find that the GLP hydrogel promotes ATDC5 cell proliferation and protects the IL-1β-induced ATDC5 cells from further OA progression by regulating the PI3K/AKT signaling pathway. Further, we show that intra-articular injection of hydrogels into an OA-induced mouse model promotes glycosaminoglycans synthesis and protects the cartilage from degradation, supporting the potential of this biomaterial for OA treatment.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

01AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Activity measurement
In mice, the liposome-anchored teriparatide and gallic acid-grafted gelatin hydrogel formed in situ after intra-articular injection.
In plain wordsIn mice, the teriparatide-containing gallic acid-grafted gelatin hydrogel formed in place after joint injection.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableIn situ hydrogel formation
Study
mousen: not reported in source
Intra-articular hydrogel injection
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
We show that the GLP hydrogel can form in situ and without affecting knee motion after intra-articular injection in mice.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we introduce a liposome-anchored teriparatide (PTH (1-34)) incorporated into a gallic acid-grafted gelatin injectable hydrogel (GLP hydrogel).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3725851001
02AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Safety outcome
In mice, intra-articular injection of the teriparatide-containing gallic acid-grafted gelatin hydrogel did not affect knee motion.
In plain wordsIn mice, the teriparatide-containing gallic acid-grafted gelatin hydrogel did not affect knee motion after joint injection.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeKnee motion
Study
mousen: not reported in source
Intra-articular hydrogel injection
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
We show that the GLP hydrogel can form in situ and without affecting knee motion after intra-articular injection in mice.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we introduce a liposome-anchored teriparatide (PTH (1-34)) incorporated into a gallic acid-grafted gelatin injectable hydrogel (GLP hydrogel).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3725851002
03AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In mice with induced osteoarthritis, intra-articular teriparatide-containing gallic acid-grafted gelatin hydrogel promoted glycosaminoglycan synthesis.
In plain wordsIn mice with induced osteoarthritis, the teriparatide-containing gallic acid-grafted gelatin hydrogel promoted glycosaminoglycan synthesis.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseGlycosaminoglycan synthesis
Study
mousen: not reported in source
OA-induced mouse model
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Further, we show that intra-articular injection of hydrogels into an OA-induced mouse model promotes glycosaminoglycans synthesis and protects the cartilage from degradation, supporting the potential of this biomaterial for OA treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we introduce a liposome-anchored teriparatide (PTH (1-34)) incorporated into a gallic acid-grafted gelatin injectable hydrogel (GLP hydrogel).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3725851007
04AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In mice with induced osteoarthritis, intra-articular teriparatide-containing gallic acid-grafted gelatin hydrogel protected cartilage against degradation.
In plain wordsIn mice with induced osteoarthritis, the teriparatide-containing gallic acid-grafted gelatin hydrogel protected cartilage against degradation.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseCartilage degradation
Study
mousen: not reported in source
OA-induced mouse model
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Further, we show that intra-articular injection of hydrogels into an OA-induced mouse model promotes glycosaminoglycans synthesis and protects the cartilage from degradation, supporting the potential of this biomaterial for OA treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we introduce a liposome-anchored teriparatide (PTH (1-34)) incorporated into a gallic acid-grafted gelatin injectable hydrogel (GLP hydrogel).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3725851008
05LabNot a test of Teriparatide (PTH 1-34) aloneIn vitro (cells)Efficacy outcome
In ATDC5 cells, the teriparatide-containing gallic acid-grafted gelatin hydrogel promoted proliferation.
In plain wordsIn cells, the teriparatide-containing gallic acid-grafted gelatin hydrogel promoted ATDC5 cell growth.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseATDC5 cell proliferation
Study
n: not reported in source
ATDC5 cells
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
We find that the GLP hydrogel promotes ATDC5 cell proliferation and protects the IL-1β-induced ATDC5 cells from further OA progression by regulating the PI3K/AKT signaling pathway.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we introduce a liposome-anchored teriparatide (PTH (1-34)) incorporated into a gallic acid-grafted gelatin injectable hydrogel (GLP hydrogel).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3725851004
06LabNot a test of Teriparatide (PTH 1-34) aloneIn vitro (cells)Efficacy outcome
In IL-1β-induced ATDC5 cells, the teriparatide-containing gallic acid-grafted gelatin hydrogel protected against further OA progression.
In plain wordsIn cells, the teriparatide-containing gallic acid-grafted gelatin hydrogel protected challenged ATDC5 cells against further osteoarthritis progression.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseOA progression in ATDC5 cells
Study
n: not reported in source
IL-1β-induced ATDC5 cells
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
We find that the GLP hydrogel promotes ATDC5 cell proliferation and protects the IL-1β-induced ATDC5 cells from further OA progression by regulating the PI3K/AKT signaling pathway.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we introduce a liposome-anchored teriparatide (PTH (1-34)) incorporated into a gallic acid-grafted gelatin injectable hydrogel (GLP hydrogel).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3725851005
07LabNot a test of Teriparatide (PTH 1-34) aloneIn vitro (cells)Mechanism
In IL-1β-induced ATDC5 cells, the teriparatide-containing gallic acid-grafted gelatin hydrogel regulated PI3K/AKT signaling.
In plain wordsIn cells, the teriparatide-containing gallic acid-grafted gelatin hydrogel regulated PI3K/AKT signaling in challenged ATDC5 cells.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicablePI3K/AKT signaling regulation
Study
n: not reported in source
IL-1β-induced ATDC5 cells
Outcome group
Receptor activity and mechanism · Musculoskeletal
Source sentences
Summary
We find that the GLP hydrogel promotes ATDC5 cell proliferation and protects the IL-1β-induced ATDC5 cells from further OA progression by regulating the PI3K/AKT signaling pathway.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we introduce a liposome-anchored teriparatide (PTH (1-34)) incorporated into a gallic acid-grafted gelatin injectable hydrogel (GLP hydrogel).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3725851006
08LabNot a test of Teriparatide (PTH 1-34) aloneIn vitro (cell-free)Activity measurement
In a hydrogel release system, teriparatide showed controlled, sustained release from the gallic acid-grafted gelatin formulation.
In plain wordsIn lab tests, the gallic acid-grafted gelatin hydrogel released teriparatide in a controlled, sustained manner.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableControlled sustained peptide release
Study
n: not reported in source
GLP hydrogel release system
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
We demonstrate controlled, sustained release of PTH (1-34) from the GLP hydrogel.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we introduce a liposome-anchored teriparatide (PTH (1-34)) incorporated into a gallic acid-grafted gelatin injectable hydrogel (GLP hydrogel).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3725851003

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.